Safety of Subcutaneous Immunotherapy with Novo-Helisen-Depot in the Children: a Retrospective Analysis from a Single Center in Northern China

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2024 May 10

PMID 38725990

Authors

Qianlan Zhou

Si Liu

Bing Dai

Li Chen

Lina Han

Qinzhen Zhang

Wenxin Shen

Lishen Shan

Affiliations

Soon will be listed here.

Abstract

Background: Little is known about the safety of mite extract product Novo-Helisen Depot (NHD) as subcutaneous immunotherapy (SCIT) in the children with mite allergy especially immediate/late local reaction (LRs).

Methods: We conducted a retrospective study analyzing the adverse events of the children undergoing subcutaneous immunotherapy with NHD. Adverse events included local and systemic adverse reactions (SRs) at the very early and late stage. The correlation of the basic characteristics, laboratory analysis results, LRs and SRs were analyzed.

Results: Two hundred and eighty-seven patients received at least 15 months of subcutaneous immunotherapy with NHD were included in the analysis. Skin-prick testing (SPT) results of was associated with an increased risk of immediate LRs in build-up phase (OR = 1.53, 95% CI: 1.02, 2.37) and delayed LRs in maintenance phase (OR = 1.58, 95% CI: 1.05, 2.46), while SPT results of was associated with an increased risk of SRs (OR = 3.22, 95% CI: 1.17, 10.00) and severe SRs (OR = 7.68, 95% CI: 1.13, 109.50). Serum IgE level of was associated with an increased risk of SRs (OR = 1.01, 95% CI: 1.00, 1.03). Patients with both asthma and allergic rhinitis was associated with an increased risk of SR, and severe SRs (< 0.05).

Conclusion: NHD as SCIT is safe. The children with higher SPT level with or , higher serum IgE level of , children with both asthma and allergic rhinitis, and the children with treatment interruption had higher risk of adverse events.

References

Epstein T, Liss G, Murphy-Berendts K, Bernstein D . AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract. 2014; 2(2):161-7. DOI: 10.1016/j.jaip.2014.01.004. View

Scadding G, Kariyawasam H, Scadding G, Mirakian R, Buckley R, Dixon T . BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2018; 47(7):856-889. DOI: 10.1111/cea.12953. View

Dick S, Doust E, Cowie H, Ayres J, Turner S . Associations between environmental exposures and asthma control and exacerbations in young children: a systematic review. BMJ Open. 2014; 4(2):e003827. PMC: 3927936. DOI: 10.1136/bmjopen-2013-003827. View

Guan K, Liu B, Wang M, Li Z, Chang C, Cui L . Principles of Allergen Immunotherapy and Its Clinical Application in China: Contrasts and Comparisons with the USA. Clin Rev Allergy Immunol. 2019; 57(1):128-143. DOI: 10.1007/s12016-019-08751-y. View

Agache I, Lau S, Akdis C, Smolinska S, Bonini M, Cavkaytar O . EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019; 74(5):855-873. DOI: 10.1111/all.13749. View

Feng M, Sun W, Cheng X . Seasonal dynamics and distribution of house dust mites in China. Biosci Trends. 2010; 3(6):210-5. View

Zhang Y, Zhang L . Increasing Prevalence of Allergic Rhinitis in China. Allergy Asthma Immunol Res. 2019; 11(2):156-169. PMC: 6340797. DOI: 10.4168/aair.2019.11.2.156. View

Sun J, Shen L, Chen J, Yu J, Yin J . Species diversity of house dust mites in Beijing, China. J Med Entomol. 2013; 50(1):31-6. DOI: 10.1603/me12036. View

. [Third nationwide survey of childhood asthma in urban areas of China]. Zhonghua Er Ke Za Zhi. 2014; 51(10):729-35. View

10.

Epstein T, Calabria C . Is immunotherapy safe for treatment of severe asthma. Curr Opin Allergy Clin Immunol. 2022; 22(6):396-401. DOI: 10.1097/ACI.0000000000000853. View

11.

Xiang L, Liu F, Zhi L, Jiang W, Liu C, Xie H . Safety of semi-depot house dust mite allergen extract in children and adolescents with allergic rhinitis and asthma. Immunotherapy. 2020; 13(3):227-239. DOI: 10.2217/imt-2020-0232. View

12.

Wilson J, Platts-Mills T . Home Environmental Interventions for House Dust Mite. J Allergy Clin Immunol Pract. 2018; 6(1):1-7. PMC: 6474366. DOI: 10.1016/j.jaip.2017.10.003. View

13.

Epstein T, Murphy-Berendts K, Liss G, Bernstein D . Risk factors for fatal and nonfatal reactions to immunotherapy (2008-2018): postinjection monitoring and severe asthma. Ann Allergy Asthma Immunol. 2021; 127(1):64-69.e1. DOI: 10.1016/j.anai.2021.03.011. View

14.

Albuhairi S, Sare T, Lakin P, El Khoury K, Crestani E, Schneider L . Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment. J Allergy Clin Immunol Pract. 2018; 6(5):1711-1716.e4. DOI: 10.1016/j.jaip.2017.11.040. View

15.

Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M . Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017; 72(12):1825-1848. DOI: 10.1111/all.13208. View

16.

Curin M, Khaitov M, Karaulov A, Namazova-Baranova L, Campana R, Garib V . Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches. Curr Allergy Asthma Rep. 2018; 18(7):39. PMC: 5994214. DOI: 10.1007/s11882-018-0790-x. View

17.

Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X . Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet. 2019; 394(10196):407-418. DOI: 10.1016/S0140-6736(19)31147-X. View

18.

Bousquet J, Khaltaev N, Cruz A, Denburg J, Fokkens W, Togias A . Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 Suppl 86:8-160. DOI: 10.1111/j.1398-9995.2007.01620.x. View

19.

Pfaar O, Agache I, de Blay F, Bonini S, Chaker A, Durham S . Perspectives in allergen immunotherapy: 2019 and beyond. Allergy. 2019; 74 Suppl 108:3-25. DOI: 10.1111/all.14077. View

20.

Bernstein D, Epstein T . Safety of subcutaneous allergen immunotherapy. Allergy Asthma Proc. 2022; 43(4):267-271. DOI: 10.2500/aap.2022.43.220035. View